Rare Malignant Neoplasm
Conditions
Brief summary
Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers. In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.
Detailed description
All patients will have the tumour cells diagnosed with a large genepanel, analyzing more than 500 genes on DNA / RNA level. Patients will be treated based on the molecular characteristics of the tumor cells.
Interventions
DRUGImatinib
imatinib treatment based on molecular alterations
DRUGTrametinib
According to biomarkers
DRUGDabrafenib
According to biomarkers
Sponsors
Helse Stavanger HF
University Hospital of North Norway
StOlavs Hospital
Nordlandssykehuset HF
Helse Nord-Trøndelag HF
Sorlandet Hospital HF
Møre og Romsdal Hospital Trust
The Hospital of Vestfold
Helse Fonna
Haukeland University Hospital
Sykehuset Ostfold
Helse Forde
Sykehuset Innlandet HF
Oslo University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
simon two stage model
Eligibility
Sex/Gender
ALL
Age
16 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* ECOG 0-2, * identified biomarker, * reasonable biochemistry
Exclusion criteria
* ECOG 3-5 * serious other diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Radiological response evaluation at 16 weeks of treatment | 16 weeks | Standard radiological response evaluation, like RECIST criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Molecular analyses predicting responses | 2 years | Sequencing of tumor material and blood samples |
Countries
Norway
Contacts
Primary ContactÅslaug Helland, MD PhD
Backup ContactKathinka Slørdahl, MD PhD
Outcome results
None listed